Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 13Thoracic 4Genitourinary 4Gynecologic 3Gastrointestinal 3Dermatologic 3Breast 3Other solid neoplasm 1Lymphoid 1

Conditions

Hodgkin Disease 36Lymphoma 34Lymphoma, Non-Hodgkin 24Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 18Lymphoma, B-Cell 16Recurrence 15Melanoma 14Neoplasms 12Mycosis Fungoides 9Lymphoma, T-Cell 9Breast Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, T-Cell, Cutaneous 7Lymphoma, B-Cell, Marginal Zone 7Head and Neck Neoplasms 7Sezary Syndrome 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lung Neoplasms 6Carcinoma, Renal Cell 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasm Metastasis 5Lymphoma, T-Cell, Peripheral 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4

Interventions

fludarabine phosphate 2fludarabine 2Cyclophosphamide 2pembrolizumab 1Quality of Life 1Patient Reported Outcome Measures 1Panobinostat 1Molecular Diagnostic Techniques 1Interleukin-2 1Immunotherapy 1Everolimus 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × pembrolizumab × Lymphoid × Clear all
NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

RAPT Therapeutics, Inc.

Phase 1/2 Completed
323 enrolled
BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡